pRED has struck its first epigenetics deal, with a $500 million-plus potential payoff for Oryzon and its orphan cancer blocker ORY-1001.
written on 07.04.2014
pRED has struck its first epigenetics deal, with a $500 million-plus potential payoff for Oryzon and its orphan cancer blocker ORY-1001.
See our Cookie Privacy Policy Here